title: Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy.
abstract: OBJECTIVE
  The authors aimed to investigate whether nanotechnology-based delivery of antigenic peptides is feasible for efficiently inducing anti-tumor cytotoxic T lymphocyte responses through vaccination.
  
  
  METHODS
  Three different murine melanoma antigens were entrapped in lipid-coated poly(D,L-lactide-co-glycolide) nanoparticles (NPs) by the double emulsion method.
  
  
  RESULTS
  The loading efficiency of hydrophilic peptides was greatly improved when lipids were introduced to formulate lipid-coated NPs. The lipid-coated NPs carrying a single peptide and/or combinations of multiple lipid-coated NPs carrying antigenic peptides were characterized in vitro and in vivo in a C57/BL6 (B6) mouse model. Both the single melanoma antigen peptide-loaded NPs and combinational delivery of lipid-coated NPs carrying different peptides could induce antigen-specific T-cell responses. However, single peptide-loaded NPs failed to significantly delay the growth of subcutaneously inoculated B16 melanoma cells in a prophylactic setting. By contrast, the combinational delivery of lipid-coated NPs carrying different peptides significantly suppressed growth of inoculated B16 melanoma cells.
authors.affiliation: Tongji School of Pharmacy, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China.
authors.forename: Songwei
authors.initials: S
authors.lastname: Tan
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sasada
authors.forename: Anna
authors.initials: A
authors.lastname: Bershteyn
authors.forename: Kunyu
authors.initials: K
authors.lastname: Yang
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Ioji
authors.forename: Zhiping
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D045744:Cell Line, Tumor; D019344:Lactic Acid / Q000737:chemistry*; D008055:Lipids / Q000737:chemistry*; D008545:Melanoma / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D053769:Nanocapsules / Q000737:chemistry* / Q000648:ultrastructure; D010455:Peptides / Q000008:administration & dosage* / Q000276:immunology; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D008055:Lipids; D053769:Nanocapsules; D010455:Peptides; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid
keywords: T-cell responses; cancer; immunotherapy; lipid-coated nanoparticle; melanoma; vaccine antigens